Jean Genève
22 Papers
486 Citations
Jean Genève is an academic researcher. The author has contributed to research in topics: Breast cancer & Docetaxel. The author has an hindex of 14, co-authored 22 publications.
Chat about Author
Papers
Perioperative Chemotherapy Compared With Surgery Alone for Resectable Gastroesophageal Adenocarcinoma: An FNCLCC and FFCD Multicenter Phase III Trial
Marc Ychou,Valérie Boige,Jean-Pierre Pignon,Thierry Conroy,Olivier Bouché,Gilles Lebreton,Muriel Ducourtieux,Laurent Bedenne,Jean-Michel Fabre,B. Saint-Aubert,Jean Genève,Philippe Lasser,Philippe Rougier +12 more
TL;DR: In patients with resectable adenocarcinoma of the lower esophagus, GEJ, or stomach, perioperative chemotherapy using fluorouracil plus cisplatin significantly increased the curative resection rate, disease-free survival, and OS.
1.9K
Sequential Adjuvant Epirubicin-Based and Docetaxel Chemotherapy for Node-Positive Breast Cancer Patients: The FNCLCC PACS 01 Trial
Henri Roché,Pierre Fumoleau,Marc Spielmann,Jean-Luc Canon,Thierry Delozier,D. Serin,Michel Symann,Pierre Kerbrat,Patrick Soulié,Françoise Eichler,Patrice Viens,A. Monnier,A. Vindevoghel,Mario Campone,Marie-Josèphe Goudier,Jacques Bonneterre,Jean-Marc Ferrero,Anne-Laure Martin,Jean Genève,Bernard Asselain +19 more
TL;DR: The PACS 01 trial as mentioned in this paper compared six cycles of fluorouracil, epirubicin, and cyclophosphamide (FEC) with a sequential regimen of three cycles of FEC followed by three cycle of docetaxel as adjuvant treatment for node-positive early breast cancer.
601
Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: The FNCLCC PACS 01 trial
Henri Roché,Pierre Fumoleau,Marc Spielmann,Jean-Luc Canon,Thierry Delozier,D. Serin,Michel Symann,Pierre Kerbrat,Patrick Soulié,Françoise Eichler,Patrice Viens,A. Monnier,A. Vindevoghel,Mario Campone,Marie-Josèphe Goudier,Jacques Bonneterre,Jean-Marc Ferrero,Anne-Laure Martin,Jean Genève,Bernard Asselain +19 more
- 01 Jan 2006
TL;DR: Sequential adjuvant chemotherapy with FEC followed by docetaxel significantly improves disease-free and overall survival in node-positive breast cancer patients and has a favorable safety profile.
377
Phase III double-blind, placebo-controlled study of thalidomide in extensive-disease small-cell lung cancer after response to chemotherapy: an intergroup study FNCLCC cleo04 IFCT 00-01.
Jean-Louis Pujol,Jean Luc Breton,Radj Gervais,Marie-Laure Tanguy,Elisabeth Quoix,Philippe David,H. Janicot,Virginie Westeel,Sabine Gameroff,Jean Genève,Dominique Maraninchi +10 more
TL;DR: Treatment with thalidomide was not associated with a significant improvement in survival of SCLC patients, and there was pronounced heterogeneity in survival outcomes between groups of patients.
147
Impact of liposomal doxorubicin-based adjuvant chemotherapy on autonomy in women over 70 with hormone-receptor-negative breast carcinoma: A French Geriatric Oncology Group (GERICO) phase II multicentre trial
Etienne Brain,C. Mertens,Véronique Girre,Frédérique Rousseau,Emmanuel Blot,Sophie Abadie,Lionel Uwer,Emmanuelle Bourbouloux,Isabelle Van Praagh-Doreau,Loic Mourey,Sylvie Kirscher,Brigitte Laguerre,Emmanuelle Fourme,Sylvia Luneau,Jean Genève,Marc Debled +15 more
TL;DR: Although chemotherapy had an impact on social and role functioning, autonomy was not impaired and toxicity was acceptable, demonstrating the feasibility of an adjuvant chemotherapy regimen combining nonpegylated liposomal doxorubicin and cyclophosphamide in fit elderly women <85 years with breast cancer.
60